More Warnings Will Further Limit Quinolone Use

September 2018

Stronger warnings will lead to more concerns about quinolone risks.

Quinolone labels already caution about hypo- and hyperglycemia...and certain CNS effects such as agitation, nervousness, or confusion.

Now FDA will require warnings of hypoglycemic coma...especially in the elderly, renal impairment, or in combo with insulin or a sulfonylurea.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Recalls Be Ready to Prescribe Alternatives to Valsartan
Diabetes Expect to Hear About Renal Protection With Newer Diabetes Meds
Cardiology Consider the Pros and Cons of the ACC/AHA CV Risk Estimator
Gout Stick With Allopurinol Instead of Febuxostat for Most Chronic Gout Patients
Cannabinoids Be Prepared With Answers About Cannabidiol
Antibiotics More Warnings Will Further Limit Quinolone Use
Diabetes & Endocrinology Use a Stepwise Approach to Treat Hirsutism
Lice Sort Through Head Lice Treatments
Menopause Watch for Imvexxy, a New Low-Dose Vaginal Estrogen
Substance Use Disorder Think of Lucemyra as Similar to Clonidine for Opioid Withdrawal
Antibiotics Don't Expect the Antibiotic Plazomicin to Be Added to Your Hospital Formulary
Bites & Stings Know the Difference Between CroFab and the New Snakebite Antivenom Anavip